Soluble Immune Checkpoints Associated With Disease Activity and Treatment Response in Graves' Disease (GD) and Thyroid Eye Disease (TED)
Authors' conclusion
The present study uncovers disturbed soluble immune checkpoints and cytokines in GD patients with and without TED and may pave the way for novel immunological screening, allowing for identification of patients with TED at higher risk of developing active disease and patients with GD a better treatment response after antithyroid drug treatment.
Study context
- Population
- Patients with GD with and without TED and healthy controls; serum 17 immune checkpoint proteins and 27 cytokines
- Participants
- 50 / 28 / 40
- Exposure
- GD with TED vs GD without TED vs healthy controls
- GD without TEDn = 50
- GD with TEDn = 28
- Healthy controlsn = 40reference
- Outcome
- Soluble immune checkpoint (sICP) and cytokine profiles
Methodological detailsquantitative multiplex analysis, follow-up in GD without TED
- Quantitative multiplex analysis
- Follow-up in GD without TED
Main finding
As reported in the abstract
- GD with TED had distinct sICP and cytokine profiles vs GD without TED
- Active TED: elevated sBTLA, sLAG-3, sGITR, sCD80, sCD86 and sPD-L1
Observational data: associations, not effects.
Further findings
TRAb improvement after antithyroid drug treatment in GD without TED · follow-up
- High baseline sBTLA, sCD27 and sCD40 associated with better improvement in TRAb titers
Functional effects of rh-GITR and rh-LAG-3 in PBMC cultures
- Increased inflammatory and decreased anti-inflammatory cytokine secretion
Original publication
Soluble Immune Checkpoints Associated With Disease Activity and Treatment Response in GD and TED. J Clin Endocrinol Metab. Published 30 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →